When the novel coronavirus hit the United States in January, Virginia Tech faculty recognized the nation was on the brink of a COVID-19 pandemic that would affect the university and the entire Commonwealth of Virginia. Hear the inside story about what happened during a virtual HokieTalk at 7 p.m. Wednesday, Sept. 30.
Ian Kimbrough, an assistant professor in the School of Neuroscience, and Jennifer Munson, an assistant professor in the Department of Biomedical Engineering and Mechanics, are taking research learned from brain tumors to help fight Alzheimer’s.
The finding gives scientists a path to understand diseases where frequent blood-brain barrier damage occurs, including traumatic brain injury, stroke, epilepsy, Alzheimer’s disease, and Parkinson’s disease.
Since June, Deborah Birx has visited universities in numerous states to learn about each institution’s approach to COVID-19. The universities that are most successful in managing COVID-19 worked hard during the summer to develop a plan for the fall semester, she said.
Staff and students at the Fralin Biomedical Research Institute at VTC, Virginia Tech Carilion School of Medicine, and the Roanoke Graduate Student Association organized two public events: a Roanoke Black History Panel on Sept. 14, and a month-long Self-Guided Gainsboro History Tour 5K.
Research expenditures are up and sponsored awards have increased by 15 percent, building upon the prior year’s expenditure total of $542 million, despite the impact of COVID-19 felt nationally by higher education institutes, according to preliminary fiscal year-end reports.
The advance will allow the university to monitor clusters of campus buildings on a daily basis, testing for the presence of the virus in fecal matter. If the testing shows positive results, the university can then conduct targeted testing among individuals to zero in on possible infections.
A multidisciplinary team is helping the university better understand and plan for impacts of COVID-19 through institution-specific models, outbreak simulations, and impact on regional hospital resources predictions.
Among the actions taken, the board approved a resolution to demolish Femoyer Hall, a 35,500-gross-square-foot facility constructed in 1949. In addition, board members toured the new Fralin Biomedical Research Institute at VTC research facility in Roanoke, the Virginia Tech School of Medicine, and new dairy facilities at Kentland Farm.
Understanding how bacteria communicate with each other helps scientists learn how to disrupt their conversations and stop infections. On Sept. 3, Bonnie Bassler will kick off the series, hosted by the Fralin Biomedical Research Institute.
During the three-day meeting, board members will receive reports on the Innovation Campus in Northern Virginia, the planning for the sesquicentennial celebration in 2022, new Title IX regulations, and the current state of university fundraising and the research enterprise.
The National Institute on Drug Abuse recently awarded a $2.6 million grant to researchers at East Tennessee State University and Virginia Tech to develop studies on how best to provide peer support services for individuals being treated for opioid use disorder.
The risks of a residential model at Virginia Tech today are different than they were in March. It is important to remember that we have vastly more information today about COVID-19 than we did in the spring.
Starting this week, as students begin to return to campus for the fall semester, the lab’s capacity of 1,000 tests per day will also be dedicated to Virginia Tech students and employees in high-contact roles.
The mandatory COVID-19 testing for on-campus residents was one of several topics related to the university’s updated plan for testing, tracing, and case management discussed during a virtual town hall with Virginia Tech leaders on July 31.
Roanoke-based cancer research startup, Acomhal Research Inc., secured a $399,878 Small Business Technology Transfer grant to determine if a molecule that stalls the spread of invasive brain cancer stem cells can help treat aggressive forms of breast cancer.